We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.
A study led by Oxford University researchers and colleagues at the National Cancer Institute, Milan, Italy has shed light on a key puzzle thrown up in some lung cancer screening programmes.
Scientists from the University of Oxford and the Leibniz-Forschungsinstitut für Molekulare Pharmakologie in Berlin have used fluorescent versions of next-generation diabetes and obesity drugs to reveal, for the first time, exactly which cells they target in the pancreas and brain.
